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patients with liver metastasis and/or 
performance status 2 and/or low albu-
min, regardless of TFI, had a poorer 
survival outlook. Therefore, chemo-
therapy sensitivity was confirmed to be 
a relevant prognostic factor and also to 
be the most important independent fac-
tor able to predict the response to sec-
ond line. Our results are in keeping with 
those of prior studies4 and of a recent 
randomized study comparing amrubi-
cin versus topotecan.5 The large sample 
size (n = 631 patients), the homoge-
neous patient population, and the com-
mon anticancer treatment (intravenous 
topotecan) strengthen the reliability of 
these results.
In contrast to our study, the 
Southwest Oncology Group multivari-
ate analysis showed that elevated lactate 
dehydrogenase, male sex, performance 
status, and weight loss ≥5, but not 
platinum sensitivity (hazard ratio, 1.25; 
p = 0.14), were independently associ-
ated with overall survival. However, 
considering a model that excluded 36 
patients who received more than one 
prior chemotherapy regimen, platinum 
sensitivity showed a positive prognostic 
impact (hazard ratio, 1.34; p = 0.049). 
Despite this, the authors developed a 
scoring system for defining prognostic 
subgroups that did not include plati-
num sensitivity. Possible weaknesses of 
the Southwest Oncology Group study 
include the small sample size (329 
patients) and the variability of second-
line therapies considered (three different 
agents including two inactive nonche-
motherapy drugs used in almost half of 
the series).
In our opinion, platinum sensitiv-
ity should continue to be considered for 
clinical practice treatment planning and 
used as stratification factor in prospec-
tive clinical trials of SCLC second-line 
treatment.
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Group (SWOG) trials of noncytotoxic 
molecular-targeted therapies in the 
platinum-treated SCLC population. We 
reported that in our pooled database, 
platinum sensitivity status was no lon-
ger as strongly associated with sub-
sequent survival after treatment with 
newer noncytotoxic agents, in contrast 
with what had been previously described 
with second-line cytotoxic therapies.
Tiseo et al. point to their own 
meta-analysis of six trials of second 
line therapy as evidence that platinum-
sensitivity status should continue to be 
considered for SCLC treatment plan-
ning and study stratification. However, 
we must point out that this meta-analysis 
was solely confined to trials of the cyto-
toxic topoisomerase inhibitor topotecan 
whereas our analysis was based on trials 
that predominantly evaluated noncyto-
toxic targeted agents. In fact, we agree 
with Kim and Mishima when they artic-
ulately emphasize this point by stating 
that our conclusions are correct “when 
noncytotoxic agents, such as molecu-
larly targeted agents, are used for sec-
ond line chemotherapy.” We, therefore, 
believe that our data set is even more rel-
evant to modern-day clinical trial design 
and planning of novel SCLC therapeu-
tics beyond that of cytotoxics.
Finally, we must emphasize that 
SWOG has done a remarkable job of 
consistently collecting the same data ele-
ments in its SCLC trials through the years. 
The availability of high quality, consistent 
data allows us to confidently pool our 
SWOG trials and expect that each data 
element is available for evaluation in our 
bivariate and multivariate models. Other 
pooled datasets or meta-analyses collect 
information from disparate trials that 
do not consistently share the same data 
elements, thus reducing confidence in 
the subsequent prognostic models.
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In Response:
We were pleased to see that our 
recent article questioning the continued 
relevance of platinum-sensitivity sta-
tus in relapsed small cell lung cancer 
(SCLC) in the modern era has stimu-
lated a healthy debate on this issue. In 
our report, we highlighted our collective 
experience within Southwest Oncology 
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